deracoxib

01/01/2006 - "The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model."
01/01/2002 - "The medium and high dosages of deracoxib were effective in preventing lameness and pain associated with synovitis. "
01/01/2006 - "Sodium urate crystals were used to create a stifle synovitis model to evaluate the efficacy of deracoxib. "
01/01/2006 - "To evaluate the efficacy of epidurally administered deracoxib to mediate the signs of a sodium urate crystal-induced stifle synovitis in dogs, and to compare the efficacy of epidural versus subcutaneously administered deracoxib. "
01/01/2002 - "Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs."

01/01/2006 - "Overall pain score for all deracoxib-treated dogs was significantly lower than for placebo dogs. "
01/01/2002 - "The medium and high dosages of deracoxib were effective in preventing lameness and pain associated with synovitis. "
01/01/2002 - "Preemptive deracoxib treatment at dosages as low as 1 mg/kg reduced lameness and pain of synovitis associated with intraarticular administration of urate crystals."
08/01/2009 - "(NAH), Greensboro, NC, USA] contains the selective COX-2 inhibitor, deracoxib, and is approved for the relief of pain and inflammation associated with orthopedic surgery and osteoarthritis in dogs. "
01/01/2007 - "This positive-control study evaluated the efficacy of firocoxib versus carprofen, deracoxib, and meloxicam for the prevention of pain and inflammation in a urate crystal synovitis model of lameness. "

04/01/2012 - "To investigate the effectiveness and safety of deracoxib (Deramaxx®) administered at a dose of 1-2 mg/kg/day for 3 days for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. "
04/01/2012 - "Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs."
01/01/2011 - "The efficacy and safety of deracoxib administered at 1-2 mg/kg/day for 3 days was assessed for the control of postoperative pain and inflammation associated with dental surgery in dogs. "
01/01/2011 - "Efficacy and safety of deracoxib for the control of postoperative pain and inflammation associated with dental surgery in dogs."
08/01/2009 - "(NAH), Greensboro, NC, USA] contains the selective COX-2 inhibitor, deracoxib, and is approved for the relief of pain and inflammation associated with orthopedic surgery and osteoarthritis in dogs. "

05/03/2016 - "In the present study, we evaluated the potential of deracoxib (DER) in potentiating antitumor activity of doxorubicin (DOX) in canine mammary carcinoma cells (CMT-U27). "
09/01/2014 - "In vitro effects of doxorubicin and deracoxib on oxidative-stress-related parameters in canine mammary carcinoma cells."
01/01/2012 - "Significant cytotoxic effects exhibited by the combination of piroxicam and deracoxib against canine mammary carcinoma cells in vitro suggest an attractive approach for the treatment of canine mammary carcinoma."
09/01/2014 - "The present study evaluated the effects of doxorubicin (DOX) and deracoxib (DER), as single agents and in combination treatments, on antioxidant parameters in the canine mammary carcinoma cell line CMT-U27. "
01/01/2012 - "The aim of our study was to determine the direct antiproliferative effects of nonsteroidal anti-inflammatory drugs (NSAIDs), piroxicam and deracoxib, at a variety of concentrations as both single and combined treatments on canine mammary carcinoma cell line CMT-U27 and to understand the mechanisms of cell death. "

01/01/2010 - "The aim of this study was to determine if there was a clinical affect of deracoxib (COX-2 selective antagonist) on dogs engaged in intense rehabilitation following tibial plateau levelling osteotomy for cranial cruciate ligament rupture. "